STOCK TITAN

1933 Industries Announces First Quarter 2023 Financial Results and Reports Record Revenue of $5.64 Million

Rhea-AI Impact
(Moderate)
Rhea-AI Sentiment
(Positive)
Tags
Rhea-AI Summary

1933 Industries Inc. (CSE:TGIF)(OTCQB:TGIFF) reported its Q1 2023 financial results, achieving record revenues of $5.64 million, a 129% increase year-over-year. The gross margin reached $2.0 million, while the company posted an adjusted EBITDA of $0.1 million. Despite a net loss of $1.2 million, management highlights a disciplined cost strategy and ongoing demand for AMA branded products. The results underscore the company's growth trajectory in the cannabis sector, despite facing pressure from competitive pricing.

Positive
  • Record revenue of $5.64 million for Q1 2023, a 129% increase from Q1 2022.
  • Achieved a gross margin of $2.0 million before fair value adjustments.
  • Top 10 selling cannabis brand in Nevada.
  • Adjusted EBITDA of $0.1 million compared to a loss in the previous year.
Negative
  • Net loss increased to $1.2 million from $0.9 million year-over-year.
  • Soft demand for hemp-infused products due to decreased wholesale demand and increased competition.

VANCOUVER, BC / ACCESSWIRE / December 28, 2022 / 1933 Industries Inc. (the "Company" or "1933 Industries") (CSE:TGIF)(OTCQB:TGIFF), a Nevada-focused cannabis consumer packaged goods company, is pleased to announce its first quarter financial results ("Q1 2023") For the three months ended October 31, 2022 and 2021 ("Fiscal 2023"). All amounts expressed are in Canadian dollars.

The Company owns 91% of Alternative Medicine Association (AMA), the Company's cultivation and production subsidiary focused on the cultivation and sale of medical and adult-use cannabis products, and 100% of CBD product manufacturer Infused MFG LLC (Infused). The Company's revenue is derived from wholesale cannabis sales in Nevada (AMA), and from the sale of hemp-derived consumer packaged goods (Infused) under the Canna Hemp brand sold across the US via ecommerce at cannahemp.com

Q1 2023 Financial Highlights

  • Total revenues of $5.64 million, marking a record of the highest quarterly revenue in the Company's history
  • Gross margin of $2.0 million before fair value adjustments
  • Adjusted EBITDA income of $0.1 million
  • Top 10 selling cannabis brand in Nevada

Consolidated Operating Highlights

Revenues

  • Total revenues were $5.64 million for Q1 2023 and $2.5 million for Q1 2022, achieving the best quarterly revenue in the Company's history. The Company attained a 129% increase in revenue compared to the same period in fiscal 2022 and a 116% increase compared to $2.6 million during the previous quarter (Q4 2022).
  • The Company's hemp-infused consumer packaged goods subsidiary recorded comparable revenues compared to the same period in fiscal 2022 with positive gross margins. Overall, demand for hemp-infused products remains soft due to decreased wholesale demand in dispensaries and brick and mortar accounts, macro-economic headwinds, and increased competition due to low barrier to entry for hemp-infused products.

Gross Margin and Profitability

  • For the three-month period ended October 31, 2022, gross margin was $2.0 million before fair value adjustments of biological asset transformation, compared to $0.6 million during the same period of the prior year. Excluding $1.3 million in fair value adjustments, the Company was profitable in the reporting quarter. The decrease in gross margin is attributable to a decrease in flower pricing in Nevada.

Expenses

  • Expenses were $1.4 million for Q1 2023 and $1.9 million for Q1 2022. It is the priority of the Company's executive management to continue to reduce costs without compromising revenue.
  • General and administration expenses were $347,676, compared to $371,176 during Q1 2022. The balance is consistent period over period based on the level of operations of the Company.

Net Loss

  • Net loss was $1.2 million for Q1 2023 and $0.9 million for Q1 2022. The increase was due primarily to the to decrease in fair value adjustments on biological assets.
  • Adjusted EBITDA was $0.1 million for Q1 2023 compared to a loss of $0.3 million for Q1 2022.

Balance Sheet

  • At the end of the reporting period, the Company had a cash balance of $3.3 million compared to $3.1 million during the same period of the prior year.

Management Commentary

Paul Rosen, Chairman and CEO of 1933 Industries commented, "We are pleased to announce measurable operational results. The Company achieved the highest quarterly revenue in the Company's history, recorded positive adjusted EBITDA, and increased gross margins before fair value adjustments, demonstrating that the Company is on the right track. AMA branded products are regularly listed as the top selling cannabis products in Nevada. Strategic relationships with wholesale dispensaries, higher volume of cannabis products and a disciplined approach to reducing expenses have led to a strong quarterly performance. Although competitive wholesale flower pricing pressure continues to impact producers in Nevada, the measures that we have implemented have resulted in significant progress towards executing on our goals."

Financial statements are prepared in accordance with International Financial Reporting Standards. Detailed information regarding the Company's financial results as well as management's discussion and analysis can be found at https://sedar.com/ and https://1933industries.com/investors/financial-information

Please note the next financial release dates in accordance with the continuous disclosure schedule set out by the British Columbia Securities Commission:

2023 Financial Release Dates

Reporting QuarterRelease Date
Q2/2023April 3, 2023
Q3/2023June 29, 2023
Q4/YE 2023November 28, 2023

About 1933 Industries Inc.

1933 Industries is a Nevada-based, growth-orientated company, focusing on the cultivation and manufacturing of a large portfolio of cannabis consumer-packaged goods in a variety of formats for both the wholesale and retail markets. Its product offerings include: THC flower, pre-rolls, and extracted products under the AMA and Level X brands for the Nevada market; Canna Hemp™, national cannabidiol (CBD) brand of infused wellness products including tinctures, gummies, topicals and sport recovery products. The Company owns 91% of Alternative Medicine Association, LC (AMA) and 100% of Infused MFG LLC (Infused).

www.1933industries.com

About Alternative Medicine Association

AMA is a licensed medical and adult-use cannabis cultivation and extraction subsidiary that produces its own branded line of unique cannabis products. AMA's extensive menu of cannabis products include: craft cannabis flower, pre-rolls, full spectrum oils, high quality distillates, proprietary blends of terpenes, vaporizer products and boutique concentrates such as shatter, crumble, batter, sugar wax, diamonds, and live resin. Ultra-craft brand Level X is an exclusive collection of exotic strains, selected specifically for their distinctive terpene profiles, high THC levels, and flavonoids. With state-of-the-art cultivation and extraction facilities based in Las Vegas, Nevada, AMA seeks to offer medical patients and recreational users alike a cannabis experience that's exceptional, potent, and consistent in quality. www.amanev.com

AMA is also licensed in Nevada as an adult-use cannabis distributor.

About Canna Hemp™

With over 65 products in its portfolio, the Canna Hemp™ brand offers products in a variety of verticals and consumption formats, including, effects-based tinctures, topicals, vape pens and cartridges, gummies, and capsules for Sleep, Relief, Calm, Focus and Energy. High-grade CBD and a proprietary blend of terpenes formulated for specific effects are key differentiators for the Canna Hemp™ line. The Company recently introduced previously untapped cannabinoids Cannabigerol (CBG) and Cannabinol (CBN) to its portfolio of products with a new line of natural tinctures and gummies.

www.cannahemp.com

For further information please contact:
Alexia Helgason, VP, IR, Marketing, Media
604-728-4407
alexia@1933industries.com

Paul Rosen, CEO
paul@1933industries.com

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

Notice regarding Forward Looking Statements: This news release contains forward-looking statements. The use of any of the words "anticipate", "continue", "estimate", "expect", "may", "will", "project", "should", "believe" and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this news release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company's disclosure documents, which can be found under the Company's profile on www.sedar.com. 1933 Industries undertakes no obligation to update publicly or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by law.

SOURCE: 1933 Industries Inc.



View source version on accesswire.com:
https://www.accesswire.com/733387/1933-Industries-Announces-First-Quarter-2023-Financial-Results-and-Reports-Record-Revenue-of-564-Million

FAQ

What were the Q1 2023 revenue results for 1933 Industries (TGIFF)?

1933 Industries reported record revenues of $5.64 million for Q1 2023, marking a 129% increase from the same quarter in 2022.

How did 1933 Industries perform in terms of profitability in Q1 2023?

The company achieved a gross margin of $2.0 million and reported adjusted EBITDA income of $0.1 million for Q1 2023.

What challenges did 1933 Industries face in Q1 2023?

The company experienced soft demand for hemp-infused products due to lower wholesale demand and increased competition.

What was the net loss reported by 1933 Industries for Q1 2023?

The net loss for Q1 2023 was $1.2 million, an increase from $0.9 million in Q1 2022.

1933 INDS INC

OTC:TGIFF

TGIFF Rankings

TGIFF Latest News

TGIFF Stock Data

3.50M
445.09M
8.73%
0.46%
Drug Manufacturers - Specialty & Generic
Healthcare
Link
United States of America
Vancouver